Week Ending January 21, 2011
Volume 19, Number 1
Notice: Because of an impending book deadline, I will continue to
publish this newsletter on a less than weekly basis – likely 1 to 2 times a month for the next several months. I apologize
for this, but promise to send my subscribers alerts when ever anything really important is in play.
This Week: All That BullMarket
The good news as
2011 rolls along is that the economy is looking far better than it did six months ago. This helps account
for the undeniable bullish uptrend of the U.S. market. As this point, trading with the trend means being
on the long side for the foreseeable future.
I can offer three interesting stocks I’ve taken significant positions in, two of which will likely have sharp
moves up (or down) within the next week.
first is Clinical Data (CLDA). It has an important date with the FDA for the approval of its anti-depressant
drug Vilazodone on January 22. Roth Capital analyst Andrew Vaino handicaps the probability of approval
at 75% and if all goes well, this is a $15 stock that should jump anywhere from 50% to 75%.
What’s good about Vilazodone is that it would be the only anti-depressant
that doesn’t interfere with sex drive – not a bad niche in a market weighed down heavily by that side effect.
But even if Vilazodone gets approval, CLDA will still likely have to find a buyer among Big Pharma to really see a
sustained stock price hike.
cautious about this one because the short interest, though falling, remains high and that often means somebody knows something
that isn’t fully disclosed yet. That said, I’m significantly long this stock.
The second stock of interest is Eastman Kodak (EK).
This is a five buck stock with strong buy technical signals from Market Edge that has an upcoming January 24 court
decision on alleged EK patent infringements by Apple and Research in Motion. A favorable ruling would goose
the stock. But even in the absence of the ruling, EK seems to be coming out of the Stone Age of film into
a digital world with some nice products across lines that exhibit some of the technological innovation Eastman Kodak used
to be famous for. Plus, EK has some other patents that it might be able to extract some royalties out of
from companies like Facebook. So I’m long this one as well.
The final stock I’ve taken a significant position in is FOLD –
Amicus Therapeutics. It’s a small biotech with a drug in progress, Amigal, that treats a rare enzyme
deficiency disease known as Fabry’s disease. It’s got a deal with GlaxoSmithKline to develop
and commercialize Amigal, it has a strong cash position, and it’s already made a nice little move since Roth Capital
initiated coverage on it.
As for an update on some of my holds: Stellar (SBOTF) is a favorite long term hold – I like the promise of
its technology. TBT, shorting the long bond, is another one of my long term holds that I hope to pay for my kid’s college
At any rate, that’s all
the news that fits for now. Bon chance.
DISCLAIMER: There are often typos in this newsletter and the culprit
has to do with the fact that much of it is dictated using Dragon Naturally Speaking. The accuracy rate is quite high, but
some silly things do slip through. So if you see something that doesn't look quite right, trust the syntax and make your own